Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | GSK3A | P49840 | 1/20 | 0.31 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 2/20 | 0.30 |
| ▸ | BRD2 | P25440 | 1/20 | 0.30 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16244913 | 0.81 | BRD3 (0.34) | BRD4BRD2BRD3 | |
| SCHEMBL25311318 | 0.73 | PRMT5 (0.30) | — | |
| SCHEMBL25104409 | 0.73 | CYP3A4 (0.30) | — | |
| SCHEMBL25310974 | 0.71 | ALDH1A1 (0.36) | — | |
| SCHEMBL18744225 | 0.69 | ATAD2 (0.37) | BRD4BRD2BRD3 | |
| SCHEMBL16339165 | 0.67 | TLR9 (0.41) | — | |
| SCHEMBL20160086 | 0.67 | ATAD2 (0.36) | BRD4BRD2BRD3 | |
| SCHEMBL22101411 | 0.66 | KDM5B (0.36) | — | |
| Hydrochloric Acid SCHEMBL29256940 | 0.66 | TLR9 (0.41) | — | |
| SCHEMBL25311603 | 0.66 | TLR9 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092066-A1 | SUBSTITUTED BICYCLIC HETEROCYCLES AS MALT-1 INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2025-03-20 | — | — | US | disclosed |
| EP-4466268-A1 | SUBSTITUTED BICYCLIC HETEROCYCLES AS MALT-1 INHIBITORS | Aurigene Oncology Limited (IN) | 2024-11-27 | — | — | EP | disclosed |
| CN-118591541-A | Substituted bicyclic heterocycles as MALT-1 inhibitors | 奥瑞基尼肿瘤有限公司 | 2024-09-03 | — | — | CN | disclosed |
| WO-2023139479-A1 | SUBSTITUTED BICYCLIC HETEROCYCLES AS MALT-1 INHIBITORS | AURIGENE ONCOLOGY LIMITED (IN) | 2023-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250092066-A1 | SUBSTITUTED BICYCLIC HETEROCYCLES AS MALT-1 INHIBITORS | MALT1, FKBP1B, FKBP1A | PIM1 146/4885SRC 283/4885GSK3A 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.